Immuneering Corporation (IMRX)
NASDAQ: IMRX · IEX Real-Time Price · USD
10.13
-0.24 (-2.31%)
At close:
Mar 27, 2023, 4:00 PM
10.33
+0.20 (1.97%)
After-hours:
Mar 27, 2023, 6:51 PM EDT
Income Statement (Annual)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.32 | 2.08 | 2.31 | 1.92 |
| Revenue Growth (YoY) | -84.76% | -10.02% | 20.41% | - |
| Cost of Revenue | 0.16 | 1.15 | 1.28 | 1.22 |
| Gross Profit | 0.16 | 0.93 | 1.03 | 0.7 |
| Selling, General & Admin | 15.61 | 8.27 | 3.11 | 2.71 |
| Research & Development | 36.27 | 26.54 | 15 | 4.28 |
| Other Operating Expenses | 0.03 | 0 | 0 | 0 |
| Operating Expenses | 51.9 | 34.81 | 18.11 | 6.99 |
| Operating Income | -51.74 | -33.89 | -17.08 | -6.29 |
| Interest Expense / Income | 0 | 0 | 0 | 0.35 |
| Other Expense / Income | -1.23 | -0.04 | -0.04 | 1.07 |
| Pretax Income | -50.51 | -33.84 | -17.04 | -7.71 |
| Income Tax | 0 | -0.31 | 0 | 0 |
| Net Income | -50.51 | -33.54 | -17.04 | -7.71 |
| Shares Outstanding (Basic) | 26 | 14 | 5 | 4 |
| Shares Outstanding (Diluted) | 26 | 14 | 5 | 4 |
| Shares Change | 93.84% | 175.00% | 40.00% | - |
| EPS (Basic) | -1.91 | -2.46 | -3.44 | -2.18 |
| EPS (Diluted) | -1.91 | -2.46 | -3.44 | -2.18 |
| Free Cash Flow Per Share | -1.70 | -2.27 | -2.96 | -1.26 |
| Gross Margin | 50.11% | 44.56% | 44.61% | 36.29% |
| Operating Margin | -16325.77% | -1629.17% | -739.01% | -327.71% |
| Profit Margin | -15937.29% | -1612.33% | -737.17% | -401.59% |
| Free Cash Flow Margin | -14148.44% | -1486.17% | -634.83% | -232.48% |
| EBITDA | -49.72 | -33.68 | -16.96 | -7.34 |
| EBITDA Margin | -15685.90% | -1619.46% | -733.74% | -382.35% |
| Depreciation & Amortization | 0.8 | 0.16 | 0.08 | 0.02 |
| EBIT | -50.51 | -33.84 | -17.04 | -7.36 |
| EBIT Margin | -15937.29% | -1627.11% | -737.17% | -383.29% |
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).